Abstract Number: 362 • ACR/ARHP Annual Meeting 2017
Patients’ Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey
Background/Purpose: Health insurance plan designs often have benefits that result in highly prescriptive patient (pt) treatment options that can result in switching of patient’s medications…Abstract Number: 2831 • ACR/ARHP Annual Meeting 2017
Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib access has been restricted by many US payers to use after…Abstract Number: 2123 • ACR/ARHP Annual Meeting 2014
Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
Background/Purpose: Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs). Coverage for…Abstract Number: 998 • ACR/ARHP Annual Meeting 2013
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…
ACR Meeting Abstracts